| Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system M Fusaroli, E Raschi, V Giunchi, M Menchetti, R Rimondini Giorgini, ... International Journal of Neuropsychopharmacology 25 (9), 727-736, 2022 | 14 | 2022 |
| Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People C Lunghi, C Trevisan, M Fusaroli, V Giunchi, E Raschi, E Sangiorgi, ... Pharmaceuticals 15 (8), 977, 2022 | 9 | 2022 |
| Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System E Raschi, M Fusaroli, V Giunchi, A Repaci, C Pelusi, V Mollica, F Massari, ... Cancers 14 (19), 4610, 2022 | 8 | 2022 |
| Deliberate self-poisoning: real-time characterization of suicidal habits and toxidromes in the food and drug administration adverse event reporting system M Fusaroli, G Pelletti, V Giunchi, C Pugliese, M Bartolucci, EN Necibi, ... Drug safety 46 (3), 283-295, 2023 | 7 | 2023 |
| Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study M Fusaroli, V Giunchi, V Battini, M Gringeri, R Rimondini, M Menchetti, ... Psychiatry and Clinical Neurosciences 77 (3), 160-167, 2023 | 7 | 2023 |
| The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco‐toxicological data to assess and potentially mitigate their diffusion to water supplies V Giunchi, M Fusaroli, E Linder, J Villén, B Wettermark, M Nekoro, ... British Journal of Clinical Pharmacology 89 (7), 2020-2027, 2023 | 4 | 2023 |
| Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach V Giunchi, M Fusaroli, M Hauben, E Raschi, E Poluzzi Drug Safety 46 (10), 921-926, 2023 | 3 | 2023 |
| Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary. M Fusaroli, V Giunchi, V Battini, S Puligheddu, C Khouri, C Carnovale, ... medRxiv, 2023.06. 07.23291076, 2023 | 1 | 2023 |
| What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System C Lunghi, M Fusaroli, V Giunchi, E Raschi, A Zongo, E Poluzzi DRUG SAFETY 45 (10), 1242-1243, 2022 | 1 | 2022 |
| Allergic History and Anaphylaxis in COVID-19 Vaccines: A Disproportionality Analysis in the FDA Vaccine Adverse Event Reporting System V Giunchi, A Niero, M Bartolucci, M Fusaroli, MS Romio, L Rossi, ... Drug Safety 45 (10), 1308-1308, 2022 | 1 | 2022 |
| Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS M Fusaroli, V Giunchi, V Battini, S Puligheddu, C Khouri, C Carnovale, ... Drug Safety, 1-14, 2024 | | 2024 |
| Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors M Sisi, G Vitale, M Fusaroli, M Riefolo, V Giunchi, A D’Errico, A Ardizzoni, ... JTO Clinical and Research Reports 4 (9), 100563, 2023 | | 2023 |
| Authors’ Reply to Cappello et al. Comment on:“Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration … M Fusaroli, G Pelletti, V Giunchi, E Raschi, F De Ponti, S Pelotti, E Poluzzi Drug safety 46 (9), 919-920, 2023 | | 2023 |
| L’impatto ambientale dei farmaci sulle acque superficiali e la sua stima attraverso i dati di utilizzo V Giunchi Recenti Progressi in Medicina 114 (6), 372-374, 2023 | | 2023 |
| The environmental impact of pharmaceuticals on surface waters and its estimation through drug utilisation data. V Giunchi Recenti Progressi in Medicina 114 (6), 372-374, 2023 | | 2023 |
| Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System. M Fusaroli, S Polizzi, L Menestrina, V Giunchi, L Pellegrini, E Raschi, ... medRxiv, 2023.11. 17.23298635, 2023 | | 2023 |
| A collection of Predicted No-Effect Concentrations of human pharmaceuticals and their metabolites V Giunchi, E Poluzzi bioRxiv, 2023.12. 12.571257, 2023 | | 2023 |
| Oral Presentation: Investigating Hidden Networks in Spontaneous Reporting Systems M Fusaroli, V Giunchi, E Raschi, E Poluzzi Drug Safety 45 (10), 1119-1120, 2022 | | 2022 |
| Hyperacute Multisystem Toxicities with Immune Checkpoint Inhibitors in the FDA Adverse Event Reporting System: The Immune-Adversome E Raschi, V Giunchi, M Fusaroli, A Ardizzoni, E Poluzzi, FD Ponti DRUG SAFETY 45 (10), 1133-1133, 2022 | | 2022 |
| Post-Marketing Safety of Anti-Calcitonin Gene Related Peptide Antibodies: A Disproportionality Analysis of the FDA Adverse Event Reporting System V Giunchi, M Fusaroli, IC Antonazzo, G Hyeraci, E Raschi, E Poluzzi, ... DRUG SAFETY 45 (10), 1245-1245, 2022 | | 2022 |
